A phase IImulti-cohort study is ongoing to assess safety and efficacy of CC-90011, an oral LSD1 inhibitor, in combination with nivolumab in pre-treated SCLC patients (NCT04350463). Here, KDM1A is linked to small cell lung carcinoma.